Biosergen
Biosergen is a Swedish biotechnology company focused on developing BSG005, an antifungal drug candidate designed for invasive fungal infections. The company is organized as a small development-stage group with operations centered on clinical development, manufacturing preparation, and regulatory work for BSG005 and related formulations.
Fiscal year 2025 · change from previous year
Development 2022–2025
Business
Share of revenueDevelopment of the core antifungal compound BSG005 for invasive fungal infections.
Work on alternative formulations intended to support future clinical use and delivery.
Preclinical, proof-of-concept, and trial preparation activities for BSG005.
GMP batch preparation, quality work, and regulatory support for advancing trials.
Customers
Biosergen does not sell a commercial product today; its end users are patients with life-threatening fungal infections, especially those who have failed standard therapies. Its development and partnering model means the near-term counterparties are regulators, clinical investigators, pharmaceutical partners, and institutions involved in antifungal drug development.
Patients with invasive fungal infections, especially cancer, transplant, and AIDS patients, are the intended treatment population for BSG005.
Specialist clinicians and hospitals would administer BSG005 in severe or rescue-therapy cases where standard antifungals fail.
Potential licensing or co-development partners that may help advance, manufacture, and commercialize BSG005.
FDA, EMA, CDSCO, academic groups, and KOLs that support trial design, approvals, and evidence generation.
Strategy
Biosergen’s strategy is to advance BSG005 through clinical development, manufacturing readiness, and regulatory engagement so the program can move into later-stage studies. The company also emphasizes strategic partnerships and international positioning, reflecting a model that may rely on external collaborators for development, funding, and eventual commercialization.
Clinical data are the main value driver for a development-stage biotech and determine whether the asset can progress.
Reliable GMP supply is required to support trials and avoid delays in development timelines.
External validation and collaboration can accelerate development and improve the path to commercialization.
Geography
Biosergen is headquartered in Sweden and operates as a Nordic biotech group with roots in Norway through Biosergen AS and Select Pharma PTY LTD. Its development program is intended for international markets, with regulatory planning explicitly referencing the U.S., Europe, and India, and patent protection described across the U.S., EU, Japan, China, Australia, and other countries.
Risks
Biosergen faces the typical risks of a clinical-stage biotech: trial failure, regulatory setbacks, manufacturing delays, and dependence on external financing. Because the company has no established commercial product, its ability to continue operations and advance BSG005 is highly sensitive to capital availability and the success of each development milestone.
- Financing shortfallImpact: CriticalLikelihood: High
As a development-stage biotech, Biosergen depends on external funding to sustain operations and trials.
Exposure: Corporate liquidity and pipeline execution
- Manufacturing and supply delaysImpact: HighLikelihood: High
The company has indicated that new drug supply and batch release are critical to continuing development.
Exposure: Clinical trial timelines
- Clinical trial failureImpact: HighLikelihood: Medium
BSG005 must continue to demonstrate safety and efficacy in later studies to create value.
Exposure: BSG005 development program
- Regulatory uncertaintyImpact: MediumLikelihood: Medium
Trial design and approval requirements from agencies can change development scope and timing.
Exposure
Accounting
Judgemental itemsThe auditor highlighted uncertainty about financing and whether cash is sufficient to continue operations.
Impact: Can affect valuation, disclosure, and investor confidence
Trial preparation, regulatory work, and manufacturing costs must be accrued as incurred.
Impact: Affects quarterly operating loss and comparability
The parent company recorded write-downs on shares in subsidiaries, which can materially affect reported results.
Impact: Can create large non-cash losses at the parent level
The group was formed through acquisition of Biosergen AS, so historical consolidation treatment matters.
Impact: Affects comparability of early-period financial statements
Similar listed companies
Publicly listed companies with a comparable business focus.
Soligenix, Inc
SNGX · Pharmaceutical Preparations
Precigen, Inc
PGEN · Pharmaceutical Preparations
NervGen Pharma Corp
NGEN · Pharmaceutical Preparations
BioInvent International
BINV · Health Care
BioInvent International is a biotechnology company focused on developing novel immuno-modulatory antibodies for cancer therapy.
Bactiguard Holding
BACTI-B · Health Care
Bactiguard Holding AB is a global MedTech company based in Stockholm, Sweden, specializing in the development of biocompatible technology to prevent infections associated with medical devices.
Biogen Inc
BIIB · Biological Products, (No Diagnostic Substances)
Biogen is a U.S.-based biopharmaceutical company built around therapies for serious neurological, immunological and rare diseases.
Last updated: 24/09/2026